1.Conway, KP, Compton, W, Stinson, FSet al. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug of use disorders: results from the National Epidemiologic Survey on alcohol and related conditions. J Clin Psychiat 2006;67:247–257.
2.Kessler, RC, Crum, RM, Warner, LAet al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997;54:313–321.
3.Sullivan, EV, Deshmukh, A, De Rosa, Eet al. Striatal and forebrain nuclei volumes: contribution to motor function and working memory deficits in alcoholism. Biol Psychiatry 2005;57:768–776.
4.Nordmann, R. Alcohol and antioxidant systems. Alcohol 1994;29:513–522.
5.Ratti, MT, Giardini, A, Soragna, D. Chronic alcoholism and the frontal lobe: which executive functions are impaired? Acta Neurol Scand 2002;105:276–281.
6.Marder, SR, McQuade, RD, Stock, Eet al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123–136.
7.Potkin, SG, Saha, AR, Kujawa, MJet al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681–690.
8.Renard, CE, Fiocco, AJ, Clenet, Fet al. Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test? Psychopharmacology 2001;159:42–50.
9.Bourin, M, Chenu, F, Prica, Cet al. Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacol 2009;206:97–107.
10.Kamei, J, Miyata, S, Sunohara, Tet al. Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test. J Pharmacol Sci 2008;108:381–384.
11.Miko̡ajczak, P, Okulicz-Kozaryn, I, Kaminska, Eet al. Lack of ifenprodil anxiolytic activity after its multiple treatment in chronically ethanol-treated rats. Alcohol Alcohol 2003;38:310–315.
12.Okulicz-Kozaryn, I, Miko̡ajczak, P, Kamińska, Eet al. Effect of naltrexone administration on short-term memory in chronically ethanol-treated outbred rats. Alcohol Alcohol 2004;39:14–19.
13.Porsolt, RD, Anton, G, Blavet, Net al. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978;47:379–391.
14.Morris, R. Development of a water-maze procedure for studying spatial learning in a rat. J Neurosci Methods 1984;11:47–60.
15.Weiss, F, Porrino, LJ. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci 2002;22:3332–3337.
16.Enomoto, T, Ishibashi, T, Tokuda, Ket al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 2008;186:197–207.
17.Ishiyama, T, Tokuda, K, Ishibashi, Tet al. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007;572:160–170.
18.Burda, K, Czubak, A, Kus, Ket al. Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep 2011;63:898–907.
19.Semba, J, Watanabe, A, Kito, Set al. Behavioural and neurochemical effects of, a novel antipsychotic drug OPC- 14597, on dopaminergic mechanisms in rat brain. Neuropharmacol 1995;34:785–791.
20.Preskorn, SH. Relating clinical trials to psychiatric practice: Part I. The case of a 13-year old on aripiprazole and fluoxetine. J Psychiatric Pract 2003;9:307–313.
21.Dyr, W, Ćwik, M, Kostowski, W. Importance of selected lines of EHP and WLP rats in studies on mechanism of ethanol effect. Alkoholizm i Narkomania 2009;22:177–187.
22.Maj, J, Rogoz, Z. Synergistic effect of pramipexole and sertraline in the forced swimming test. Pol J Pharmacol 1999;51:471–475.
23.Pae, CU, Serretti, A, Patkar, AA. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008;22:367–388.
24.Joca, SR, Skalisz, LL, Beijamini, Vet al. The antidepressant-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission. Eur Neuropsychopharmacol 2000;10:223–328.
25.Renard, CE, Dailly, E, David, DJet al. Neurochemical changes following the mouse forced swimming test but not the tail suspension test. Int J Neuropsychopharmacol 2003;17:449–455.
26.Renard, CE, Dailly, E, Nic Dhonnchadha, BAet al. Is dopamine a limiting factor of the antidepressant-like effect in the mouse forced swimming test? Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1255–1259.
27.Snigdha, S, Neill, J. Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behav Brain Res 2008;191:26–31.
28.Sams-Dodd, F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol 1996;7:3–23.
29.Urban, JD, Vargas, GA, Zastrow, MVet al. Aripiprazole has functionally selective actions at D2 receptor-mediated signaling pathways. Neuropsychopharmacology 2007;32:67–77.